Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS

2022
Written By CCRG CCRG Admin

Li Bassi G, Gibbons K, Suen JY, Dalton HJ, White N, Corley A, Shrapnel S, Hinton S, Forsyth S, Laffey JG, Fan E, Fanning JP, Panigada M, Bartlett R, Brodie D, Burrell A, Chiumello D, Elhazmi A, Esperatti M, Grasselli G, Hodgson C, Ichiba S, Luna C, Marwali E, Merson L, Murthy S, Nichol A, Ogino M, Pelosi P, Torres A, Ng PY, Fraser JF; COVID-19 Critical Care Consortium. Critical Care DOI 10.1186/s13054-022-03983-5

Background: The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis.

CCRG CCRG Admin
Previous

Postoperative Pulmonary Complications in Patients with Transcatheter Tricuspid Valve Implantation—Implications for Physiotherapists
Next

Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure